In-vivo therapeutic efficacy trial with artemisinin derivative, XXXX and imidocarb dipropionate against Babesia equi infection in @entity15382 .

@entity697 @entity42271 @entity53864 @entity15382 @entity1485 @entity506 @entity743 @entity47400
The therapeutic efficacy of @entity47400 , @entity506 , @entity42271 , @entity53864 and @entity42271 + @entity53864 combination was evaluated against @entity743 equi of Indian origin in splenectomised @entity15382 with experimentally induced @entity697 . Efficacies of these drugs were tested by administering each drug or drug combination to groups of @entity15382 (having three @entity15382 each group). One group of @entity15382 was kept as untreated control for comparing the results. Parasitaemia, haematology (WBC, RBC, @entity1485 , granulocytes and haemoglobin), biochemical parameters (SAST, SALT, alkaline phosphatase, albumin/globulin ratio) were monitored at regular intervals. Individually, @entity42271 and @entity53864 were found to have no parasite clearing efficacy and the treated animals died within 5-6 days after showing high parasitaemia and clinical symptoms of the disease. However, @entity506 treated animals were able to restrict the parasite multiplication but only during the treatment period. Animals treated with @entity47400 and @entity42271 + @entity53864 combination were able to clear the parasite from the blood circulation after 2-5 days post-treatment (PT). After 55-58 days PT, recrudescence of B. equi parasite was observed in both these groups and a mean survival period of 66 days and 69 days, respectively, was recorded in these groups. Results of haemato-biochemical parameters had shown that @entity47400 had deleterious effect on the liver function while on the other hand @entity42271 + @entity53864 combination was found to be safe. This limited study indicates that @entity42271 + @entity53864 combination could be a better choice than @entity47400 for treating B. equi infection, but further trials are required in detail.
